Omniab, Inc. · NASDAQ:OABI
Omniab — Q2 2025 Earnings Presentation
20 slides from Omniab's earnings presentation, Aug 6, 2025
Slide 1: Q2 2025 Financial Results & Business Update
1 Q2 2025 Financial Results & Business Update Nasdaq: OABI August 6, 2025
Slide 2: Disclaimer
2 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, including our financial guidance fo
Slide 3: Introduction
Omni > Introduction Matt Foehr
Slide 4: Q2 2025 Highlights
4 Q2 2025 Highlights Deal flow and new partner additions accelerating, facilitated by our differentiated technologies Continued partner pipeline advancement Sold and installed xPloration® instrument within weeks of launch - strong interest from partners for technology that is expected to be accretiv
Slide 5: Active Partners
5 Active Partners Q2 2025: 100 ACTIVE PARTNERS Number of Active Partners Partner Type 100 100 Academic • We continue to grow and diversify our 11% Discovery partnership base, with 100 Active Partners as Commercial 68% of 6/30/2025 21% • New licenses added in Q2 include those with Veraxa Biotech AG,
Slide 6: Active Programs
6 Active Programs Q2 2025: 381 ACTIVE PROGRAMS YTD 2025 Change in Number of Active Programs Active Programs 400 381 45 381 • 381 Active Programs as of 363 6/30/2025 (27) • Strong 1H 2025 for additions, balanced by attrition 200 • Net addition of 18 programs year-to-date, more than double the net add
Slide 7: Active Programs and Potential Downstream Economics
7 Active Programs and Potential Downstream Economics Number of Active Programs License Type for Active Programs • ~99% of Active Programs have contracted future 400 381 Small Molecule Ion Channel Grandfathered/ 2% Prepaid License economics to OmniAb 1% Revenue Share 7% • Total remaining milestones f
Slide 8: Post-Discovery Stage Programs
8 Post-Discovery Stage Programs 22% GROWTH OVER THE LAST 12 MONTHS • Continued growth and progression As of 6/30/2024 As of 6/30/2025 of Post-Discovery stage programs Registration: 1 Registration: 1 Approved: 3 • Increasing diversity of therapy Phase 3: 2 Approved: 3 Phase 3: 6 areas within Preclini
Slide 9: Active Clinical Programs and Approved Products
9 Active Clinical Programs and Approved Products Number of Active Clinical Programs and Approved Products(1)(2) 32 • 32 active clinical programs and approved products as of 6/30/2025 30 • One new OmniChicken-derived program entered a first-in-human clinical trial in Q2 ‒ Seismic Therapeutics’ S-4321
Slide 10: Clinical and Commercial-Stage Partner Pipeline
Clinical and Commercial-Stage Partner Pipeline 10 (1)(2) AS OF 6/30/2025 ONLY PROGRAMS WITH DOWNSTREAM ECONOMICS ARE SHOWN Phase 1 Phase 2 Phase 3 Registration Approved Johnson & Joh nson Aptevo Therapeu tics CTTQ Pharma Genmab JNJ-70218902 Mipletamig TQB2223 Acasunlimab Gloria Biosciences, Arcus Bi
Slide 11: Select Partner Updates
11 Select Partner Updates IMVT-1402 TEV-53408 JNJ-79635322 M9140 FcRn IL-15 BCMA x GPRC5D x CD3 CEACAM-5 A randomized, placebo-controlled, double- Teva announced that the FDA granted Fast Johnson & Johnson presented initial Phase Merck KGaA presented dose optimization blind Phase 3 study to assess t
Slide 12: xPloration Partner Access Program Launch
12 xPloration Partner Access Program Launch • xPloration is an innovative and highly leverageable technology ‒ Poised to significantly enhance and drive efficiencies in our partners' capabilities for antibody discovery and screening, potentially enabling more OmniAb-derived programs • Now creating n
Slide 13: Financial Updates
13 Financial Updates Kurt Gustafson
Slide 14: Q2 2025 Revenue
14 Q2 2025 Revenue $ in millions $10 • xPloration revenue primarily includes sale of instrument and related consumables $7.6 License & • License and Milestone revenue was lower due to Milestone lower milestone revenue $5 $3.9 • Service Revenue decreased primarily due to the xPloration discontinuatio
Slide 15: Q2 2025 Costs and Operating Expense
15 Q2 2025 Costs and Operating Expense $ in millions $25 $23.9 Other • Research and Development expense decreased primarily due to lower stock-based compensation $20.1 $20 Other expense, lower headcount as well as lower G&A external expenses associated with small-molecule ion channel programs $15 G&
Slide 16: Q2 2025 vs. Q2 2024 Financial Results
16 Q2 2025 vs. Q2 2024 Financial Results (in millions, except per share data) Q2 2024 Q2 2025 Variance License and milestone revenue $ 3.1 $ 1.2 ($ 1.9) Service revenue 4.2 1.9 (2.2) xPloration revenue 0.0 0.6 0.6 Royalty revenue 0.3 0.1 (0.2) Total revenue 7.6 3.9 (3.7) Cost of xPloration revenue -
Slide 17: Balance Sheet
17 Balance Sheet (in millions) December 31, June 30, 2024 2025 ASSETS Current assets: Cash & investments $ 59.4 $ 41.6 Accounts receivable, net 5.3 2.7 Other current assets 3.4 3.3 • Cash use in the quarter was Goodwill & intangible assets 222.0 215.6 $2 million PPE & leases 33.3 30.8 Other assets 2
Slide 18: 2025 Guidance – No Change from Previous Quarter
18 2025 Guidance – No Change from Previous Quarter • Revenue expected to be in the range of $20 to $25 million • Operating expense to be in the range of $85 to $90 million • 2025 cash use expected to be lower than cash use in 2024(1) • 2025 effective tax rate expected to be approximately 0% due to v
Slide 19: Q&A
Omni Q&A
Slide 20: Omni >
Omni >